Interviews

In part 2 of her AMCP Nexus 2026 interview, Jennifer S. Graff, PharmD, discusses improving patient experience data (PED) standardization and credibility.

At AMCP Nexus 2026, experts discussed how drug pricing policy, AI, and high-cost cell and gene therapies may shape managed care in 2027.

In part 2, Leanna Baker, PharmD, MS, of Cencora discusses the ongoing costs, governance, and oversight needed for responsible AI adoption.

Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.

At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.

Crescent Moore, PharmD, PhD, discusses provider, coverage, stigma, and education barriers to menopause therapy access.

Karin Johnson, MD, says permanent daylight saving time won’t boost exercise or road safety and that sleep loss from spring clock changes harms health.

Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.

Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for advanced practitioner-led care.

Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.

Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.

Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

Adam Colborn, JD, discusses 340B reform, PBM policy, site-neutral payment, and other federal health policy issues to watch in 2027.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower treatment costs.

Jennifer S. Graff, PharmD, said payers need clearer standards to assess the reliability and credibility of patient experience data.

Oyepeju Abioye-Akintola, MD, MSc, says unreadable consent forms are a fixable barrier to oncology trial enrollment.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what matters most to AYA patients.

Managed care organizations should start AI adoption with simple tools that build governance for future growth, Leanna Baker, PharmD, MS, said.

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.

At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

Clinicians at CHEST 2026 say costs and outcomes are shaped well beyond the ICU, from surgical choices to discharge planning and end-of-life talks.

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Karin Johnson, MD, urges Congress to back permanent standard time, citing sleep, heart, and teen health risks of daylight saving time.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.